hematological malignancies

PATIENT TESTIMONY

This is the testimony from a Follicular Lymphoma patient who acheived remission on this trial: her desperate situation before going on the trial, her experience going through immunotherapy, to being told she was in remission. 

There have been remarkable results of anti-PD1 causing remissions in heavily pretreated Hodgkin's Lymphoma patients.

Here we examine why this cancer immunotherapy can change the way Hodgkin's Lymphoma patients are treated in the future.

Hodgkin's Lymphoma is a good target for anti-PD1.

Anti-PD1 treatments are showing tremendous results for Hodgkin's Lymphoma patients who have not responded to conventional treatments.

The results are coming out at the American Society of Hematology (ASH) conference, December 2014 and creating great excitement.